ORCID "0000-0001-7934-7039" Makale Koleksiyonu için listeleme
-
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gürbüz, Mustafa; Kutlu, Yasin; Akkuş, Erman; Köksoy, Elif Berna; Köse, Naziyet; Öven, Bala Başak; Oyan Uluç, Başak; Demiray, Atike Gökçen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Üskent, Necdet; Akbaş, Sinem; Selçukbiricik, Fatih; İnal, Ali; Bilici, Ahmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Ünal, Çağlar; Hizal, Mutlu; Şendur, Mehmet Ali Nahit; Korkmaz, Mustafa; Karadurmuş, Nuri; Ertürk, İsmail; Göksu, Sema Sezgin; Tatlı, Ali Murat; Güven, Deniz Can; Kılıçkap, Saadettin; Paksoy, Nail; Aydıner, Adnan; Yeşil Çınkır, Havva; Özkul, Özlem; Öztürk, Akın; Ballı, Sevinç; Kemal, Yasemin; Erdoğan, Atike Pınar; Er, Özlem; Yumuk, Perran Fulden; Demirkazık, Ahmet (Springer, 2022)Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In ... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin (Elsevier, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum resistant urothelial carcinoma. Objective: To compare ... -
Clinicopathological and survival characteristics of mismatch repair status and PD-1 expression in serous ovarian cancer
Ölmez, Fatma; Oğlak, Süleyman Cemil; Akgöl, Sedat; Ölmez, Ömer Fatih; Bilici, Ahmet; Akbayır, Özgür; Gedik Özköse, Zeynep; Can, Esra; Ünal, Ömer; Acar Şirinoğlu, Hicran (College of Physicians and Surgeons Pakistan, 2023)Objective: To evaluate the clinicopathological characteristics of mismatch repair (MMR) deficiency and its clinical outcomes by performing immunohistochemistry (IHC) for MMR genes in the serous ovarian cancer (SOC) tumour ... -
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study
Akdeniz, Nadiye; Kaplan, Muhammet Ali; Uncu, Doğan; İnanç, Mevlüde; Kaya, Serap; Dane, Faysal; Küçüköner, Mehmet; Demirci, Ayşe; Bilici, Mehmet; Gök Durnalı, Ayşe; Koral, Lokman; Şendur, Mehmet Ali Nahit; Erol, Cihan; Türkmen, Esma; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Laçin, Şahin; Şahinli, Hayriye; Urakçı, Zuhat; Işıkdoğan, Abdurrahman (Springer, 2021)Purpose We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal ... -
The comparison of local tumor control after microwave ablation, surgical resection and combined treatment for colorectal liver metastases
Güngören, Fatma Zeynep; Erol, Cengiz; Bilici, Ahmet; Dayangaç, Murat; Şeker, Mehmet; Ölmez, Ömer Fatih; Yaprak, Onur; Yıldız, Özcan; Öncel, Mustafa (ValpoScholar-Valparaiso University, 2022)Aim. We aimed to compare the local therapeutic efficiency of microwave ablation (MWA), surgical resection, and combined treatment, assess the outcomes, and identify predictive factors for local treatment response in ... -
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
Şenocak Taşçı, Elif; Kutlu, Yasin; Ölmez, Ömer Fatih; Mutlu, Arda Ulaş; Gündoğdu, Yasemin; Seyyar, Mustafa; Şahin, Elif; Çabuk, Devrim; Majidova, Nargiz; Uğurlu, İrem; Demirci, Ayşe; Aydın, Dinçer; Çavdar, Eyyüp; Bayram, Selami; Yıldırım, Nilgün; Karataş, Fatih; Karakurt Eryılmaz, Melek; Çağlayan, Dilek; Menekşe, Serkan; Kut, Engin; Arak, Hacı; Keser, Murat; Sunar, Veli; Perkin, Perihan; Şakalar, Teoman; Oyan, Başak; Sönmez, Özlem; Özer, Leyla; Yıldız, İbrahim (2024)Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard ... -
Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Akar, Emre; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek; Karadurmuş, Nuri; Kılıçkap, Saadettin (CIG Media Group, 2023)This 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Ireland Ltd, 2020)Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ... -
High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer
Ölmez, Fatma; Oğlak, Süleyman Cemil; Ölmez, Ömer Fatih; Akbayır, Özgür; Yılmaz, Ercan; Akgöl, Sedat; Konal, Merve; Seyhan, Niyazi Alper; Kinter, Alp Koray (Turkish Society of Obstetrics and Gynecology, 2022)Objective: The current study assesss programmed death-1 (PD-1) receptor expression and CD3, CD4, and CD8 tumor-infiltrating lymphocytes (TILs) in high-grade serous ovarian cancer (HGSOC) and to associate our results with ... -
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
Bilici, Ahmet; Ölmez, Ömer Fatih; Kaplan, Muhammed Ali; Öksüzoğlu, Berna; Sezer, Ahmet; Karadurmuş, Nuri; Çubukçu, Erdem; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Demirci, Umut (Taylor & Francis Ltd, 2023)AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ... -
Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Ölmez, Ömer Fatih; Karcı, Ebru (Lippincott Williams & Wilkins, 2023)... -
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Kutlu, Yasin; Hamdard, Jamshid; Muğlu, Harun; Ölmez, Ömer Fatih; Karcı, Ebru; Açıkgöz, Özgür (Elsevier B.V., 2023)Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ... -
Major and minor salivary gland cancers: A multicenter retrospective study
Hacıoğlu, Muhammet Bekir; Erdoğan, Bülent; Bardakçı, Murat; Algın, Efnan; Gülbağcı, Burcu; Hacıbekiroğlu, İlhan; Hamdard, Jamshid; Ölmez, Ömer Fatih; Akkuş, Hadi; Çiçin, İrfan (John Wiley and Sons Inc, 2023)BackgroundMost of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. ... -
Meme kanserli hastalarda kemoterapi sonrası bilişsel fonksiyonların aktivite performansı ve aktivite katılım üzerine olan etkisi
Akdemir, Gülhizar; Ünsal, Esra; Tarakçı, Devrim; Bilici, Ahmet; Ölmez, Fatih Ömer; Yıldız, Özcan (AVES, 2021)Amaç: Bilişsel fonksiyon problemleri kemoterapinin en yaygın yan etkileri arasında yer almaktadır. Bireyler tedavi bittikten sonra da bilişsel fonksiyon bozuklukları yaşamaya devam etmektedir. Meme kanseri atlatan bireyler ... -
Metastatik meme kanseri tedavisinde lapatinib kapesitabin kombinasyonun etkinliğinin retrospektif değerlendirilmesi
Tüm dünyada meme kanseri kadınlarda kanserin ve kanser ilişkili ölümlerin en sık nedenidir. Meme kanserli hastaların %17-30 HER2overekspresyonu olup hastalık, kötü prognoz, hastalık progresyon riskinde artış, genel sağkalım ... -
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
Kutlu, Yasin; Göktaş Aydın, Sabin; Bilici, Ahmet; Öven, Bala Başak; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Hamdard, Jamshid (NLM (Medline), 2023)Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ... -
The optimal treatment approaches and prognostic factors in elderly patients with advanced stage biliary tract tumors
Göktaş Aydın, Sabin; Çakan Demirel, Burçin; Bilici, Ahmet; Yılmaz, Cansu; Topçu, Atakan; Aykan, Musa Barış; Kahraman, Seda; Atcı, Muhammed Mustafa; Akbıyık, Ilgın; Akgül, Fahri; Ölmez, Ömer Fatih; Aydın, Ahmet (Ankara Hematology Oncology Association, 2023)Introduction: There is a lack of evidence of the outcomes in elderly patients advanced stage biliary tract cancer due to the patients aged over 65 years are less than 25% in many prospective trials. We designed a retrospective ... -
Papilödem: Leptomeninjiyal metastazın önemli klinik işareti olabilir mi?
Arıcı Düz, Özge; Olmuşçelik, Oktay; Çadırcı, Fadime; Ölmez, Ömer Fatih (Galenos Yayıncılık, 2020)Amaç: Leptomeninjiyal metastaz (LM) tüm kanser tiplerinde izlenebilen nadir ancak kötü prognozlu bir klinik tablodur. Tanı, tedavi ve prognoz hastalığı yönetmekte önemli süreçlerdendir. Bu amaçla LM klinik ve laboratuvar ... -
Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
Açıkgöz, Özgür; Çakan, Burçin; Demir, Tarık; Bilici, Ahmet; Öven, Bala Başak; Hamdard, Jamshid; Olmuşçelik, Oktay; Ölmez, Ömer Fatih; Şeker, Mesut; Yıldız, Özcan (Lippincott Williams & Wilkins, 2021)The aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. ... -
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Aydın, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Karcı, Ebru; Bilici, Ahmet; Ölmez, Ömer Fatih; Yıldız, Özcan (Springer, 2024)Background: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic ...